Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler’s pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape.Prescription & OTC DrugsOur pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation.Infectious Disease TreatmentsSterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases.Generic Drug DevelopmentWe work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

In the News

August 19, 2026

Double Patenting Ripe for Fresh Fed. Circ. To Clarify Things

Law360

Articles

August 18, 2026

AI Is Inventing Molecules: Why U.S. Patent Law Must Allow Owners of Inventions To File Patent Applications Without Naming Inventors

IDEA: The Law Review of the Franklin Pierce Center for Intellectual Property

Articles

August 17, 2026

Europe’s Missing Biotech Bridge: Why IP Ownership Matters More Than Capital Access

Life Sciences Intellectual Property Review